Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present a corporate overview and hold investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference.

The event is virtual on February 25, 2026 with a presentation at 3:20 PM ET; a webcast link will be provided for investors.

Key Figures

Conference edition: 36th Annual Conference date: February 25, 2026 Presentation time: 3:20 p.m. ET

3 metrics

Conference edition 36th Annual Oppenheimer Healthcare Life Sciences Conference

Conference date February 25, 2026 Virtual Oppenheimer Healthcare Life Sciences Conference

Presentation time 3:20 p.m. ET Scheduled time for corporate overview presentation

Market Reality Check

Price: $7.83 Vol: Volume 126,743 is below t...

normal vol

$7.83 Last Close

Volume Volume 126,743 is below the 20-day average of 162,673 (relative volume 0.78). normal

Technical Shares at $7.62 are trading below the 200-day MA of $9.86 and sit 62.94% under the 52-week high of $20.56.

Peers on Argus

CRBP fell 3.79% while peers were mixed: BMEA -4.04%, PYXS -0.74%, KALA -4.35%, b...

CRBP fell 3.79% while peers were mixed: BMEA -4.04%, PYXS -0.74%, KALA -4.35%, but EQ and FATE rose 1.31% and 6.36%, respectively. This points to stock-specific trading rather than a clear sector-wide move.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Investor conference	Neutral	-0.5%	Announced CEO presentation at J.P. Morgan Healthcare conference with webcast access.
Dec 11	Clinical data update	Positive	-5.7%	Reported Phase 1a CRB-913 obesity data with favorable safety and early weight loss.
Dec 10	Data timing update	Neutral	+1.6%	Outlined timing for Phase 1a CRB-913 obesity data release and webcast details.
Nov 12	Earnings and update	Positive	+7.4%	Q3 2025 results, CRB-701 efficacy data, cash raise, and runway into 2028.
Nov 06	Investor conferences	Neutral	-4.2%	Planned participation in multiple healthcare investor conferences with webcasts.

Pattern Detected

Conference participation headlines for CRBP have typically seen modest or negative next-day moves, while substantial clinical and financial updates have produced mixed reactions, including one notable selloff despite positive obesity Phase 1a data.

Recent Company History

Over the last few months, Corbus has mixed routine conference participation with more material updates. A Nov 12, 2025 Q3 2025 update highlighted CRB-701 efficacy data and a public offering raising about $73.8M, with shares reacting positively by 7.39% the next day. In contrast, favorable Phase 1a obesity data on Dec 11, 2025 saw a -5.65% move. Prior and subsequent investor-conference announcements (e.g., J.P. Morgan, multi-conference participation) produced modest price changes, suggesting this Oppenheimer conference news fits a pattern of lower-impact, investor-relations-oriented headlines.

Market Pulse Summary

This announcement centers on Corbus’ participation in the 36th Annual Oppenheimer Healthcare Life Sc...

Analysis

This announcement centers on Corbus’ participation in the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026, with a virtual corporate overview at 3:20 p.m. ET and investor meetings. It follows recent clinical, financial, and governance updates, including prior conference appearances and Phase 1a obesity data. Investors may watch for how management frames the oncology and obesity pipeline, prior financing that added about $73.8M, and previously communicated cash runway into 2028.

AI-generated analysis. Not financial advice.

NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36^th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026.

36^th Annual Oppenheimer Healthcare Life Sciences Conference
Format: Virtual presentation and one-on-one investor meetings
Date: February 25, 2026
Presentation Time: 3:20pm Eastern Time
Webcast Link: Click Here

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

FAQ

When will Corbus Pharmaceuticals (CRBP) present at the Oppenheimer Healthcare Life Sciences Conference?

Corbus will present on February 25, 2026 at 3:20 PM Eastern Time. According to the company, CEO Yuval Cohen will deliver a corporate overview and participate in one-on-one investor meetings during the virtual conference.

Who from Corbus (CRBP) is presenting at the February 25, 2026 virtual conference?

CEO Yuval Cohen, Ph.D., is the scheduled presenter for Corbus (CRBP). According to the company, he will present a corporate overview and be available for investor meetings during the virtual event.

How can investors watch Corbus Pharmaceuticals (CRBP) present on February 25, 2026?

Investors can watch via the event webcast provided for the virtual conference. According to the company, a webcast link will be made available for the February 25, 2026 presentation at 3:20 PM ET.

What topics will Corbus (CRBP) cover in the February 25, 2026 presentation?

The presentation will provide a corporate overview and investor engagement by Corbus leadership. According to the company, CEO Yuval Cohen will discuss the company's clinical-stage programs in oncology and obesity and meet with investors one-on-one.

Will Corbus Pharmaceuticals (CRBP) hold investor meetings at the 36th Annual Oppenheimer conference?

Yes; Corbus will hold one-on-one investor meetings in addition to the presentation. According to the company, CEO Yuval Cohen will attend investor meetings during the virtual conference on February 25, 2026.